---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001504"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:42:58.578670+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones

## Summary
- Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).
- Cash $237.7M at Sep 30, 2022, down from $370.5M at Dec 31, 2021.
- CSL Seqirus collaboration: $200M upfront, up to $4.3B milestones, 40% profit share on COVID vaccines.
- BARDA award of up to $63.2M for self-amplifying mRNA pandemic influenza vaccine development.
- ARCT-810 OTC deficiency Phase 2 dosing starts Q4 2022; ARCT-032 CTA filing expected by year end.

## SEC filing metadata
- accession: 0001193805-22-001504
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/0001193805-22-001504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/e618005_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001504
- JSON: https://secwatch.observer/filing/0001193805-22-001504.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001504.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $13.4 million, net income net loss of approximately $35.3 million, or ($1.33) per basic and diluted share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $13.4 million
  - Net income: net loss of approximately $35.3 million, or ($1.33) per basic and diluted share
  - Result: reported results
  source text: from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended September 30, 2022, the Company reported revenue of $13.4 million compared with $2.4 million for the three months ended September 30, 2021, and $27.1 million for the three months ended June 30, 2022. Revenue increased by $10.9 million during
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/0001193805-22-001504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.